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Abstract
Background—Local recurrence (LR) rates in patients with retroperitoneal sarcoma (RPS) are
high, ranging from 40% to 80%, with no definitive studies describing the best way to administer
radiation. Intraoperative electron beam radiation therapy (IOERT) provides a theoretical
advantage for access to the tumor bed with reduced toxicity to surrounding structures. The goal of
this study was to evaluate the role of IOERT in high-risk patients.
Methods—An institutional review board approved, single institution sarcoma database was
queried to identify patients who received IOERT for treatment of RPS from 2/2001 to 1/2009.
Data were analyzed using the Kaplan–Meier method, Cox regression, and Fisher Exact tests.
Results—Eighteen patients (median age 51 y, 25–76 y) underwent tumor resection with IOERT
(median dose 1250 cGy) for primary (n = 13) and recurrent (n = 5) RPS. Seventeen patients
received neoadjuvant radiotherapy. Eight high-grade and 10 low-grade tumors were identified.
Median tumor size was 15 cm. Four patients died and two in the perioperative period. Median
follow-up of survivors was 3.6 y. Five patients (31%) developed an LR in the irradiated field.
Three patients with primary disease (25%) and two (50%) with recurrent disease developed an LR
(P = 0.5). Four patients with high-grade tumors (57%) and one with a low-grade tumor (11%)
developed an LR (P = 0.1). The 2- and 5-y OS rates were 100% and 72%. Two- and 5-y LR rates
were 13% and 36%.
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Conclusions—Using a multidisciplinary approach, we have achieved low LR rates in our high-
risk patient population indicating that IOERT may play an important role in managing these
patients.
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1. Introduction
Soft tissue sarcomas are rare tumors and represent only 1% of cancers diagnosed in the US
for an annual incidence of 11,280 cases [1]. Retroperitoneal sarcomas (RPS) represent
approximately 12%–15% of all sarcomas. Because of the rarity of this tumor type, there is
little definitive data in the literature regarding management. The gold standard of treatment
remains surgical resection with negative margins. However, given the location of these
tumors and the often large size at the time of presentation, it is difficult to achieve wide
margins at the time of surgery. As a result, the benefit of a multidisciplinary approach to
determine which patients are at a high risk is essential. Local recurrence (LR) rates for RPS
can range from 40% to 80% with 5 y overall survival (OS) historically at 50% [2–8].
Seventy-five percent of deaths in patients with RPS are due to LR [9,10]. Radiation therapy
in conjunction with surgery has been shown to reduce rates of LR in high-risk sarcomas,
particularly in extremity sarcoma [11]. However, the delivery of radiation in patients with
RPS presents a clinical dilemma. In extremity soft tissue sarcomas, external beam radiation
therapy (EBRT) at doses of >6400 cGy can be administered with minimal toxicity or
damage to surrounding structures and negative margins can usually be obtained [10].
However, due to the deep nature of the tumor, these parameters are not easily accomplished
when treating RPS.
RPS arise in close proximity to vital organs such as bowel, kidney, and liver. It is often
difficult or impossible to deliver effective doses of EBRT to the entire tumor bed without
significant toxicity to these surrounding structures. As a result, IOERT provides a theoretical
advantage over EBRT in treating these tumors. IOERT allow for sufficient delivery of
radiation directly to the tumor bed while placing vital organs outside the field of radiation to
reduce toxicity. Additionally, IOERT can provide a boost of radiation therapy to areas that
would otherwise be difficult to control with surgery and EBRT. IOERT is also useful in
patients who have previously received EBRT present with a recurrence. Despite these
theoretical advantages, there are no clear indications in the literature for when IOERT is
most beneficial.
Few studies have been able to evaluate the benefits of IOERT use in patients with high-risk
RPS due to the rarity of this tumor type. Given the potential advantages of incorporating
IOERT into the management of patients with RPS, we sought to analyze our experience to
add to the existing body of research and improve the treatment of this locally aggressive
disease. We hope to provide further information on the risk of local regional failure after
resection and IOERT.
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Patients were selected from a single institution, prospective database that has been approved
by our institutional review board. Patients were identified for the sarcoma database using
operative case logs. Hospital medical records were reviewed for clinic notes, radiology
reports, operative notes, and pathology reports. In addition, social security death records
were reviewed for each patient. All patients who underwent IOERT for treatment of either
primary or recurrent RPS from April 2002 to January 2009 were included in this study, for a
total of 18 patients.
Radiation was administered intraoperatively via a Mobetron device (IntraOp Medical,
Sunnyvale, CA) in a dedicated OR staffed for IOERT administration. Intraoperative
radiation doses ranged from 1000 to 2000 cGy. Most patients also received neoadjuvant
radiation therapy to a dose of approximately 4500 cGy. Radiation doses varied depending on
whether the tumor was being treated initially or there had been radiation delivered
previously and whether there was pathologic or clinical evidence of positive margins.
Patients who had not been previously irradiated generally received preoperative EBRT to a
dose of 45 Gy (4500 cGy) over 5 wk. At the time of surgery, if they received preoperative
radiation therapy and there was no evidence of a positive margin but the patient was thought
to still be at risk of local failure because of the infiltrative nature of the tumor, an additional
10 Gy was used postoperatively. If there was greater concern for margin positivity, then a
dose of 1500 cGy was generally used. For patients who did not receive EBRT, a dose of
12.5–15 cGy was used for negative margins and a dose up to 20 Gy for positive margins or
known residual tumor.
Four surgical oncologists performed the surgical procedures. A tumor board consisting of
surgical oncologists, radiation oncologists, surgical pathologists, and medical oncologists
collaboratively made the decision for IOERT. Although there were no set criteria for
recommending that a patient receive IOERT, the patients selected for this approach were
those thought to be at high-risk patients for LR due to factors such as high grade, large
tumor size, or proximity to vital organs.
2.1. Statistical methods
Percentages of development of LR were compared between groups using Fisher Exact test,
and the Kaplan–Meier method was used to compare OS and time to LR between categories.
Cox regression was used to estimate the association between tumor size and OS and time to
LR. OS was calculated as the time from operation at UNC when IOERT was delivered to the
date of death or last follow-up. Time to LR was calculated as the time from operation to the
date of LR or last follow-up. The upper bound of the 95% confidence interval (CI) for
median time to LR could not be estimated due to censoring.
3. Results
A total of 18 patients were included in the study. Four patients died and two deaths were
perioperative and the other two patients died of disease. The median follow-up of survivors
was 43 mo (range 3–98 mo), and all but one patient had >1 y of follow-up. Of the 18
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patients included in the study, 13 (72%) had primary disease and five (28%) presented with
recurrent disease. There were an equal number of males and females. Eleven patients (61%)
were white and seven patients were black (39%). The median age was 51 y (range 25–76 y).
Half of the tumors were liposarcomas, five (28%) were leiomyosarcomas, two were
malignant fibrous histiocytoma (11%), and there was one sarcomatoid carcinoma and one
tumor that could not be classified into a specific histologic type. Eight of the tumors were
high grade and 10 were low grade. Median tumor size was 15 cm (range 3–41 cm). Margins
were R0 in 16 (89%) and R1 in 2 (11%) (Table 1).
All 18 patients received IOERT with a median dose of 1250 cGy (range 1000–2000).
Seventeen of these patients also received neoadjuvant radiotherapy with a median dose of
4500 cGy (range 4500–5040).
Postoperative complications included an anastomotic leak (n = 1), a chyle leak (n = 1), and a
retroperitoneal abscess (n = 1).
Sixteen of the 18 patients were available for analysis of LR as a result of the two
perioperative deaths. Five patients (31%) developed an LR, none of which were in the
setting of distant metastasis. Three of the evaluable patients (25%) with primary disease and
two of the evaluable patients (50%) with recurrence disease experienced an LR (P = 0.5).
Four patients with high-grade tumors (57%) and one patient with low-grade tumors (11%)
had an LR (P = 0.1) (Table 2). Median time to LR was 6.08 y (95% CI: 2.37). The 2- and 5-
y LR free rates were 87% (95% CI: 56.4%–96.5%) and 64% (95% CI: 27.8%–85.8%). No
significant differences were noted in time to LR in patients with primary versus recurrent
disease (P = 0.7), high-versus low-grade lesions (P = 0.2), multivisceral resection (P =
0.18), or larger tumor size at presentation (P = 0.6) (Fig. A). Three of the five patients with
LR underwent re-resection and had no evidence of disease at the time of the study. The other
two patients died of disease approximately 2 and 3 y later.
The 2- and 5-y OS rates were 100% and 72% (95% CI: 23.4%–92.8%). No significant
differences were noted in OS in patients with primary versus recurrent disease (P = 0.3),
high-versus low-grade lesions (P = 0.8), multivisceral resection (P = 0.5), or larger tumor
size at presentation (P = 0.9) (Fig. 1B).
4. Discussion
Our study examines the recurrence patterns and OS of 18 RPS patients treated with IOERT.
Our results support existing data that IOERT does play an important role in managing
patients with high-risk RPS. In this high-risk patient population, our LR rate of 31% and 5-y
OS of 72% are quite favorable. There have been a small number of historical studies
examining outcomes in patients with RPS, which convey the aggressive nature of this
disease consistent with our findings [4,12–15] (Table 3). Due to the small size of our study,
we were not able to perform multivariate analysis to determine specific factors associated
with recurrence and OS in the setting of IOERT. However, we saw no statistically
significant difference in time to LR or OS when comparing high-versus low-grade lesions,
primary versus recurrent disease, large tumor size or multivisceral resection, suggesting that
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the LR and OS benefits can be achieved by all these subgroups in carefully selected
populations.
There are a small number of studies exploring the use of IOERT in patients with RPS. These
studies have found similar recurrence rates to our study [3,10,16–18] (Table 4). In the study
of 28 patients by Yoon et al., the importance of negative margins is again discussed as the
best method of controlling disease. Twelve of the 28 patients in their study received IOERT
in cases of close or positive posterior margins and they postulate that IOERT may be an
important tool in helping to sterilize posterior margins and margins that would otherwise be
hard to access with surgery alone. In the study by Geischen et al., a comparison is made
between patients receiving neoadjuvant radiation and surgery alone, to neoadjuvant radiation
plus IOERT. A total of 37 patients are included in their study, 20 of whom received IOERT.
In comparing those patients receiving IOERT with patients who did not, the authors
demonstrate a clear improvement in local control and OS in patients receiving IOERT in
their carefully selected patient population with 5-y OS of 74% in the IOERT group
compared with 30% in the neoadjuvant alone group. Consistent with these findings, our 5-y
OS rate of 72% is substantially improved over historical rates around 50%.
IOERT can be administered with a complication profile similar to that of EBRT. Some
studies report increased neurotoxicity in patients receiving IOERT due to the proximity of
the administered dose to neurovascular bundles [5,19–21]. We report on all postoperative
complications but do not elaborate on radiation-specific complications. However, an earlier
study at our institution by Caudle et al. reported that complication rates with neoadjuvant
radiotherapy and IOERT were comparable to complications with neoadjuvant radiation
therapy alone. In this study, five of the 14 patients studied received IOERT in addition to
neoadjuvant radiation therapy with no difference in side effect profiles [22]. This is
consistent with more recent studies suggesting that more favorable toxicity profiles with
preservation of recurrence and survival benefits can be achieved at lower accepted doses of
IOERT [23].
The limitations of this study are that it is a single institution, retrospective analysis and like
most studies of treatment modalities in RPS, there are a small number of patients. Despite
these limitations, we have been able to provide valuable data regarding our experience with
IOERT in this rare and challenging patient population. The results of our study are easily
translatable to current patient populations in that none of our patients received
chemotherapy, virtually all received EBRT preoperatively, and IOERT was administered at
low relative doses.
In our study, we did not use specific criteria to determining that a patient is an appropriate
candidate for IOERT. However, there are some characteristics that are associated with a
high risk of LR. Patients with high-grade tumors and large tumor size are at greater risk for
recurrence. Specific to IOERT as a modality, patients with tumors that closely abut vital
structures, particularly neurovascular structures, are potential candidates for IOERT. Finally,
patients who have already received radiation can have IOERT as a boost of radiation in a
previously irradiated field. Ultimately, we use a multidisciplinary approach to decision
making to make a final recommendation for IOERT.
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Our results indicate that improved LR rates can be achieved using multimodality treatment
including IOERT in patients with high-risk RPS. More robust studies are needed to better
characterize the advantages of IOERT and to further delineate which patients receive the
greatest benefit from this treatment modality. Previous attempts at randomized controlled
trials of IOERT have been limited by difficulty in accruing a substantial patient population
given the rarity of this tumor type. The one small randomized controlled trial of 35 patients
conducted in 1993 by Sindelar et al. found an improved incidence of LR with use of
intraoperative radiation therapy (IORT) (n = 15) versus postoperative EBRT alone with six
of 16 patients receiving IORT experiencing an LR compared with 16 of the 20 patients who
received EBRT alone. However, some patients in this trial received chemotherapy, which is
currently not the standard of care and IORT doses were higher than currently accepted doses
resulting in higher rates of neuropathy [5].
In tumors such as RPS in which local failure is the primary contributor to disease morbidity
and mortality, improved methods of local control are of great importance. Results from our
study and review of the literature support the idea that IOERT is indeed a powerful tool in
sterilizing local margins and improving local control and therefore disease-associated
mortality.
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(A) Time to LR was generated and analyzed from the date of diagnosis using the Kaplan–
Meier method. The 5-y LR free rate for our patient population is 64%. (B) OS was generated
and analyzed from the date of diagnosis using the Kaplan–Meier method. The 2- and 5-y OS
rates for our patient population are 100% and 72%, respectively.
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Table 1
Demographics and tumor characteristics.
Variable N (%)
Total patients 18
Median follow-up 43 mo (3–98)
Median age (range) 51 (25–76)
Gender
  Male 9 (50%)
  Female 9 (50%)
Race
  White 11 (61%)
  Black 7 (39%)
Presentation
  Primary disease 13 (72%)
  Recurrence disease 5 (28%)
Histology
  Liposarcoma 9 (50%)
  Leiomyosarcoma 5 (28%)
  MFH 2 (11%)
  Other 2 (11%)
Grade
  Low (1, 2) 11 (61%)
  High (3, 4) 7 (39%)
Margin status
  R0 16 (89%)
  R1 2 (11%)
Median tumor size (cm) 15 (3–41)
MFH = Malignant Fibrous Histiocytoma.
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Table 2
Local recurrence.
Variable LR N LR rate (%)
All patients 5 16 31
Primary disease 3 12 25
Recurrent disease 2 4 50
High grade 4 7 57
Low grade 1 9 11
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Table 4
Local control and survival with use of IOERT in RPS.
Author Year N 5-y LRFS (%) 5-y OS (%)
Sindelar 1993 15 31* 37*
Alektiar 2000 32 62 45
Geischen 2001 16 83 74
Tran 2008 39 24 30†
Yoon 2010 12 60 36
Our study 18 64 72
*
Estimated from survival curves.
†
Disease-specific survival.
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